TrophiCell is a biotechnology company developing a proprietary stem cell platform designed to overcome key barriers in cell therapy and enable scalable therapeutic and industrial applications.

The company’s technology is based on research originating at the University of Liverpool and focuses on translating advanced stem cell science into clinically and commercially viable solutions.

TrophiCell’s platform harnesses the responsive trophic repair and immunomodulatory properties of Mesenchymal Stromal Cells (MSCs), enabling the development of standardised, scalable advanced therapies optimised for a range of clinical indications. The approach addresses fundamental challenges in the field, including reproducibility, scalability, and regulatory translation.

The company is pursuing a partnership-led model, working with leading manufacturing and clinical organisations to accelerate development and deliver life-enhancing therapies in areas of significant unmet clinical need.